Thursday, 28 March 2019 09:00
Hotel Bildungszentrum 21, Missionsstrasse 21, 4055 Basel, Switzerland
This email address is being protected from spambots. You need JavaScript enabled to view it.

"Translating biomarker candidates from discovery to the clinic remains a challenge. This second symposium organised by the Clinimark project will examines how integrated technologies can bridge the innovation gap with an initial focus on lung diseases."


Joseph Menetski, PhD. Associate Vice President of Research Partnerships - Director of the Biomarkers Consortium, the Foundation for the National Institutes of Health, USA


• Biomarker research and development
• Biomarker validation process and techniques
• Biomarker FDA regulation
• Pulmonary Diseases including COPD, oncology, cystic fibrosis
• Biobanking and data stewardship
• Technologies (mass spectrometry, multiplex immunoassays, new approaches to quantify proteins in body fluids and breath condensate)


• Clinicians
• Clinical chemists
• Biologists (molecular biology, biochemistry, epidemiology)
• Scientists with an interest in biomarker technology
• Industrial scientists (start-up, diagnostic, pharmaceutical, biotechnological)


Registration until March 20, 2019
The official language of the conference is English,
A registration fee of 100 euro will apply to Clinimark external participants.
all Clinimark members registered for the Clinimark bi-annual workshop (March 29 – 30, Basel) are automatically registered for the symposium free of charge and do not need to register separately to this event.



Hotel Bildungszentrum 21, Missionsstrasse 21, 4055 Basel, Switzerland

see more


09.15 – 09.30: Opening of the symposium
Peter Groenen, PhD. Head of Translational Sciences, Idorsia Pharmaceuticals Ltd, Switzerland; Theo Luider, PhD. Erasmus MC, The Netherlands

09.30 – 10.15: Embracing Team Science to Create Drug Development Tools for Clinical Decision
Joseph Menetski, PhD. Associate Vice President of Research Partnerships - Director of the Biomarkers Consortium, the Foundation for the National Institutes of Health, USA

10.15 – 10.45: Cellular biomarker method validation and application in phase 1 clinical trials
Bernhard Reis, PhD. Senior Principal Scientist, Roche Innovation Center Basel, Switzerland

10.45 – 11.15: Coffee break

11.15 – 11.45: An introduction to Digital Clinical Trials and Digital Biomarkers
Laurenz Baltzer, Strategy Competence Lead, Karger AG, Switzerland

11.45 – 12.15: Proteomic biomarkers in breath
Marian Hajduch, Prof. Dr. med, Director, Institute of Molecular and Translational Medicine (IMTM), Czech Republic

12.15 – 12.45: Biomarkers in respiratory diseases
María Jesús Cruz, PhD. Pneumology Research Group, Vall d'Hebron Research Institute (VHIR), Spain

12.45 – 14.00 Lunch

14.00 – 14.30: Genomic Biomarkers: Role in Predictive Medicine and in Deciphering Causation for other Molecular Biomarkers
Vincent Mooser, Prof. Laboratory Medicine, Head Clinical Chemistry, Lausanne University Hospital (CHUV), Switzerland

14.30 – 15.00: Biomarker Best Practices: confounding factors, preanalytics and method validation
Rainer Bischoff, Prof. Head Department of Analytical Biochemistry. University of Groningen, the Netherlands

15.00 – 15.30: The use of Biological Reference Material for Biomarker Validation
Monica Marchese, PhD. Biomarker Validation Scientist, Integrated Biobank of Luxembourg (IBBL), Luxembourg

15.30 – 16.00: Break

16.00 – 16.30: Precision medicine: biomarker concepts for asthma patient endotyping in drug development
Daniel Strasser PhD. Associate Director, Idorsia Pharmaceuticals Ltd., Switzerland

16.30 – 17.00: Targeted mass spectrometry-based proteomics (SWATH-MS / DIA) to identify and characterize biomarkers in complex samples
Peter Blattmann, PhD. Postdoctoral Scientist, Institute of Molecular Systems Biology (ETH), Switzerland

17.00 – 17.30: Clinical application of X-omics biomarkers for personalized diagnostics
Alain van Gool, Prof. Head Translational Metabolic Laboratory, Radboudumc, The Netherlands